Empliciti market seen growing on rising multiple myeloma cases through 2030

The Business Research Company says the Empliciti market is set for significant expansion from 2026 to 2030 as multiple myeloma cases rise, oncology spending climbs and demand grows for targeted immunotherapies. North America led the market in 2025, while the report points to broader adoption of combination biologics and personalized treatment approaches.

Why it matters: - Empliciti is tied to the growing multiple myeloma treatment market, where rising case counts and longer survival rates are increasing demand for long-term biologic therapies. - The market outlook matters for oncology drug developers, hospitals and payers because the report points to stronger use of immunotherapy and other targeted cancer treatments through 2030.

What happened: - The Business Research Company published its Empliciti Market Segmentation Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 3, 2026. - The report says the Empliciti market is poised for significant growth from 2026 to 2030. - Empliciti, or elotuzumab, is a prescription monoclonal antibody used to treat multiple myeloma. - The drug works by targeting the SLAMF7 protein on myeloma cells and natural killer cells to help the immune system attack cancer.

The details: - Historical growth in the Empliciti market is linked to more multiple myeloma cases, limits of conventional chemotherapy, early gains from monoclonal antibodies, more cancer treatment centers and higher oncology research investment. - Future growth is expected to come from wider adoption of immunotherapy protocols, more monoclonal antibody candidates in development, better survival rates, favorable reimbursement for oncology biologics and advances in immune-based drugs. - The report highlights combination monoclonal antibody therapies, immune system-targeted cancer treatments, personalized care for multiple myeloma patients, broader use of immunotherapy in oncology and longer biologic treatment regimens as major trends. - Rising multiple myeloma incidence is a key growth driver because the cancer can damage bones, kidneys and immune function. - The American Cancer Society estimated about 35,780 new multiple myeloma cases in the United States in 2024, including 19,520 in men and 16,260 in women, along with about 12,540 expected deaths. - The report says demand for targeted cancer therapies is also supporting growth because these treatments aim at molecular markers and can spare healthy tissue. - The Royal College of Radiologists reported that demand for systemic anti-cancer therapies, including chemotherapy, increased 6% to 8% in 2023. - Rising healthcare expenditure is another support for the market because it helps fund advanced cancer therapies, infrastructure and research. - The UK Office for National Statistics reported a 5.6% nominal increase in total healthcare expenditure from 2022 to 2023, compared with 0.9% growth the year before. - North America held the leading regional position in the Empliciti market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also says its 2026 edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and key technology and future trend analysis. - The report offers a free sample and a full version online. More information the full report

Between the lines: - The report frames Empliciti as part of a broader shift toward precision oncology, where treatment growth is increasingly tied to immune-based therapies rather than traditional chemotherapy. - North America’s lead suggests the market is still most established in systems with higher oncology spending, stronger reimbursement and deeper access to specialty care.

What's next: - The report expects more combination biologic regimens and personalized multiple myeloma care to shape demand through 2030. - Ongoing growth in oncology research, immunotherapy use and healthcare spending should continue to support the market outlook. - The Business Research Company says it is adding more strategic intelligence tools in its 2026 market reports, including dashboards, infographics and future trend analysis.